The Comparison of Plasma and Cerebrospinal Fluid R(−)- and S(+)-Flurbiprofen Concentration After Intravenous Injection of Flurbiprofen Axetil in Human Subjects

por Yao, Han, Luo, Xingxian, Zhang, Hong, An, Haiyan, Feng, Wanyu, Feng, Yi
Publicado 2021

Therapeutic Drug Monitoring and Individualized Medicine of Dasatinib: Focus on Clinical Pharmacokinetics and Pharmacodynamics

por He, Shiyu, Bian, Jialu, Shao, Qianhang, Zhang, Ying, Hao, Xu, Luo, Xingxian, Feng, Yufei, Huang, Lin
Publicado 2021

Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China: A Systematic Review and Meta-Analysis

por Luo, Xingxian, Du, Xin, Li, Zhuangqi, Liu, Jingwen, Lv, Xufeng, Li, Haoran, Guo, Qixiang, Wang, Cen, Xue, Xuecai, Le, Kaidi, Jiang, Xiaomeng, Huang, Lin, Yang, Yue
Publicado 2023

Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022

por Luo, Xingxian, Du, Xin, Huang, Lin, Guo, Qixiang, Lv, Xufeng, Wang, Cen, Liu, Haopeng, Zhou, Yue, Xue, Xuecai, Li, Zhuangqi, Liu, Jingwen, Chow, Shein-Chung, Yang, Yue
Publicado 2023

The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis

por Luo, Xingxian, Du, Xin, Huang, Lin, Guo, Qixiang, Tan, Ruijie, Zhou, Yue, Li, Zhuangqi, Xue, Xuecai, Li, Taifeng, Le, Kaidi, Qian, Feng, Chow, Shein-Chung, Yang, Yue
Publicado 2022